Business Context and Reporting Period
Company: Welltower Inc. (NYSE: WELL)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Welltower is a Real Estate Investment Trust (REIT) and S&P 500 company focused on the "silver economy," owning and operating over 2,500 seniors and wellness housing communities across the United States, United Kingdom, and Canada. The company operates through three primary segments: Seniors Housing Operating, Triple-net, and Outpatient Medical. It is structured as an umbrella partnership REIT (UPREIT), with operations conducted through Welltower OP LLC.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenues | $10.84 billion | $7.99 billion | +35.6% |
| Net Income | $961.8 million | $972.9 million | -1.1% |
| Net Income Attributable to Common Stockholders (NICS) | $936.8 million | $951.7 million | -1.6% |
| Funds From Operations (FFO) | $1.82 billion | $2.32 billion | -21.8% |
| Consolidated Net Operating Income (NOI) | $4.35 billion | $3.16 billion | +37.6% |
| Adjusted EBITDA | $4.17 billion | $3.15 billion | +32.3% |
| Cash and Cash Equivalents | $5.03 billion | $3.51 billion | +43.3% |
| Total Debt (Carrying Value) | $19.20 billion | $15.50 billion | +23.9% |
| Net Debt to Book Capitalization | 25.2% | 26.8% | -1.6 pts |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 35.6% to $10.84 billion, driven primarily by significant acquisitions in the Seniors Housing Operating segment (Barchester and HC-One in the U.K.) and the Triple-net segment. Seniors Housing Operating revenues grew 41% to $8.49 billion.
- Net Income Decline: Despite revenue growth, Net Income decreased slightly by 1.1% to $961.8 million. This was largely due to a massive one-time stock-based compensation expense of $1.56 billion related to the "Ten Year Executive Continuity and Alignment Program" and increased general and administrative expenses.
- FFO Decrease: FFO attributable to common stockholders declined 21.8% to $1.82 billion. The decline is attributed to the large stock-based compensation charge and increased depreciation/amortization from new acquisitions, partially offset by higher NOI.
- Major Disposition: The company entered a definitive agreement to sell its outpatient medical portfolio for approximately $7.2 billion. As of year-end, 241 properties had been sold, generating a gain of $881.4 million.
- Acquisitions: Total cash disbursed for acquisitions was $13.91 billion, significantly higher than the $3.53 billion in 2024. Key acquisitions included the Barchester and HC-One portfolios in the U.K.
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management emphasizes a strategy of protecting stockholder capital and enhancing value through consistent dividends and portfolio growth. The company continues to invest in the "silver economy" with a focus on affluent micro-markets. The company declared a quarterly cash dividend of $0.74 per share for Q4 2025, marking the 219th consecutive quarterly dividend.
Key Risks and Contingencies:
- Regulatory & Reimbursement Risk: Significant exposure to changes in Medicare and Medicaid reimbursement policies. The "One Big Beautiful Bill Act" (OBBBA) passed in 2025 may reduce Medicaid spending and enrollment, potentially impacting operator revenues and ability to pay rent.
- Interest Rate Risk: Elevated interest rates increase borrowing costs and may impact the valuation of assets. The company has $4.06 billion in variable-rate debt (net of hedges) as of year-end.
- Foreign Currency Risk: Approximately 26.8% of assets and 20.0% of revenues are located in the U.K. Fluctuations in the GBP/USD exchange rate impact financial results.
- Stock-Based Compensation: The $1.56 billion expense recognized in 2025 related to the new executive compensation program is a significant non-cash charge that impacted reported earnings.
- Outpatient Medical Disposition: The ongoing sale of the outpatient medical portfolio involves execution risk regarding the timing and final terms of the remaining tranches expected to close through mid-2026.
Investor Verification Checklist
- Verify Stock-Based Compensation Impact: Confirm the non-cash nature of the $1.56 billion compensation expense and its specific impact on FFO and Adjusted EBITDA reconciliations.
- Monitor Outpatient Medical Sale Progress: Track the closing of the remaining tranches of the $7.2 billion outpatient medical portfolio sale and the reinvestment of proceeds.
- Assess U.K. Acquisition Integration: Review the integration and performance of the Barchester and HC-One acquisitions, which significantly increased the U.K. revenue mix to 20%.
- Review Dividend Sustainability: Analyze the company's ability to maintain the $0.74 quarterly dividend given the high capital deployment and debt levels, despite strong NOI growth.
- Check Regulatory Developments: Monitor the implementation details of the OBBBA and its specific impact on Medicaid reimbursement rates for the company's operators.